Bipolar Disorders最新文献

{"title":"Is maintenance therapy warranted for recurrent mania in a woman with a positive family history of Huntington's disease?","authors":"Amarins Gaastra, Erik van Duijn, Annemiek Dols","doi":"10.1111/bdi.13420","DOIUrl":"10.1111/bdi.13420","url":null,"abstract":"<p>A 63-year-old woman visited our outpatient clinic 2 months after being involuntarily admitted for a manic psychotic episode. She had been convinced that a bomb would hit her home and that she could talk to angels. When she was admitted, she was initially reluctant to take medication, but she quickly recovered with 10 mg of olanzapine per day and she was discharged after 3 weeks and 2 days. Her physical health is good except for osteoporosis and hypothyroid function. She does not use alcohol or drugs. She works as a legal assistant and will retire soon. She is divorced and has two daughters and two grandchildren.</p><p>Her psychiatric history revealed several (hypo)manic episodes (Figure 1). Her first manic episode likely resulted from sleep deprivation when she was 23 years old, and she recovered without needing medication after being admitted to a psychiatric ward. Her second episode of mania occurred at the age of 42 and was attributed to stress as a result of her divorce. This time around, she had to be admitted involuntarily. Then, she had three hypomanic episodes at ages 48, 51, and 58 of which she recovered without any intervention by mental healthcare professionals. She did not recall the duration of any of these last three episodes.</p><p>Despite her doubts about having bipolar disorder, she attended a psychoeducational course and attributed her episodes to psychosocial stressors, such as work-related problems and worries about her grandchild. There is no family history of psychiatric disorders, but she has a positive family history of Huntington's disease (HD), comprising seven genetically confirmed cases in one generation and symptomatic suspected cases in three successive generations. Her mother passed away at the age of 84, without an official HD diagnosis as shown in Figure 2. Our patient chose not to be genetically tested for HD as there is no cure yet. However, her two daughters decided to be tested. One of her daughters tested positive for HD, with a relatively low number of trinucleotide CAG repeats. While the exact number is not known, she was informed that a very late onset of HD was to be expected. The other daughter tested negative.</p><p>Since HD is an autosomal-dominant hereditary disease, it is highly probable that our patient has an HD gene expansion in a similar range as her daughter's. Although she had decided not to be tested for HD, our patient wondered if this could explain her vulnerability to developing psychiatric symptoms in response to psychosocial triggers and whether maintenance therapy with medication would be warranted.</p><p>Unipolar mania is classified as bipolar disorder in DSM 5 and is typically defined by three manic episodes without a depressive episode over the course of more than 5 years. Unipolar mania is a rare disorder and is clinically distinct with male predominance, earlier age at onset, shorter episodes, fewer suicide attempts, and lower lifetime comorbidities. The prevalence of unipolar ma","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":"26 3","pages":"300-302"},"PeriodicalIF":5.4,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bdi.13420","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140130634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antidepressant monotherapy in treatment-refractory bipolar II depression","authors":"Takeshi Terao","doi":"10.1111/bdi.13419","DOIUrl":"10.1111/bdi.13419","url":null,"abstract":"","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":"26 4","pages":"390-392"},"PeriodicalIF":5.4,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140118688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing clinical practice and discovery research through revised taxonomy: Case in point bipolar disorder diagnosis","authors":"Anne Duffy, Paul Grof","doi":"10.1111/bdi.13415","DOIUrl":"10.1111/bdi.13415","url":null,"abstract":"<p>In the well-articulated paper by Malhi et al.<span><sup>1</sup></span> in this journal, several problems with diagnosing bipolar disorder in children are discussed and as rightly pointed out “impede our ability to conduct meaningful research and advance clinical practice”. In fact, one could argue that the diagnostic challenges outlined apply to the diagnoses of mood disorders more generally. That is, reliance on a diagnostic checklist that reflects largely non-specific symptoms that cross diagnostic boundaries and are open to interpretation yield a highly heterogeneous population of mood disordered patients that share the same diagnosis but little else—differing in clinical course, family history, prognosis, treatment response and genetic and neurobiological correlates.</p><p>Malhi et al. offer a novel solution to the current diagnostic dilemma. The authors express hope that revising the current taxonomy so as to focus on developmentally sensitive symptom clusters, reflecting the evolution of the disorder over development, will advance the field past the current stalemate and improve diagnostic accuracy. While we agree that a developmental lens provides an informative perspective through which to view psychopathology, there is no evidence that a sole focus on symptoms, no matter how well developmentally nuanced, will improve diagnostic classification. Rather, substantive evidence supports the need to identify more homogenous subtypes from within the current heterogeneous bipolar diagnostic construct to advance risk prediction, pharmacotherapy, and discovery research. Three bipolar subtypes based on distinct clinical profiles have been described based on research extending over six decades, each with preferential response to stabilizing treatment with lithium, antipsychotics and antiepileptics, respectively (Figure 1).<span><sup>2</sup></span> Therefore, an alternative evidence-based solution would be to include these bipolar subtypes in a revised taxonomy.</p><p>Specifically, substantive evidence supports that a long-term response to lithium identifies a more homogeneous subtype of bipolar disorder characterized by a recurrent episodic course, complete remission, a history of episodic mood disorders in family members, and distinctive genetic correlates.<span><sup>3</sup></span> This distinctive clinical profile, identified by multivariate analyses, was actually delineated by Kraepelin over a century ago. Further, prospective longitudinal studies of the offspring of lithium responsive (LiR) and lithium non-responsive (LiNR) bipolar parents have provided evidence that bipolar disorder debuts as a depressive episode in adolescence, years on average before emergence of the first manic episode.<span><sup>4</sup></span> The developmental history and clinical course differ between subgroups, with offspring of LiRs having normal or gifted development and offspring of LiNRs manifesting neurodevelopmental disorders (ADHD, learning difficulties). Childh","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":"26 3","pages":"286-288"},"PeriodicalIF":5.4,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bdi.13415","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140058586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of established and off-label ADHD drug therapies for cognitive impairment or attention-deficit hyperactivity disorder symptoms in bipolar disorder: A systematic review by the ISBD Targeting Cognition Task Force","authors":"Kamilla W. Miskowiak,&nbsp;Zacharias K. Obel,&nbsp;Riccardo Guglielmo,&nbsp;Caterina del Mar Bonnin,&nbsp;Christopher R. Bowie,&nbsp;Vicent Balanzá-Martínez,&nbsp;Katherine E. Burdick,&nbsp;Andre F. Carvalho,&nbsp;Annemieke Dols,&nbsp;Katie Douglas,&nbsp;Peter Gallagher,&nbsp;Lars V. Kessing,&nbsp;Beny Lafer,&nbsp;Kathryn E. Lewandowski,&nbsp;Carlos López-Jaramillo,&nbsp;Anabel Martinez-Aran,&nbsp;Roger S. McIntyre,&nbsp;Richard J. Porter,&nbsp;Scot E. Purdon,&nbsp;Ayal Schaffer,&nbsp;Paul R. A. Stokes,&nbsp;Tomiki Sumiyoshi,&nbsp;Ivan J. Torres,&nbsp;Tamsyn E. Van Rheenen,&nbsp;Lakshmi N. Yatham,&nbsp;Allan H. Young,&nbsp;Eduard Vieta,&nbsp;Gregor Hasler","doi":"10.1111/bdi.13414","DOIUrl":"10.1111/bdi.13414","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Abnormalities in dopamine and norepinephrine signaling are implicated in cognitive impairments in bipolar disorder (BD) and attention-deficit hyperactivity disorder (ADHD). This systematic review by the ISBD Targeting Cognition Task Force therefore aimed to investigate the possible benefits on cognition and/or ADHD symptoms and safety of established and off-label ADHD therapies in BD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We included studies of ADHD medications in BD patients, which involved cognitive and/or safety measures. We followed the procedures of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 statement. Searches were conducted on PubMed, Embase and PsycINFO from inception until June 2023. Two authors reviewed the studies independently using the Revised Cochrane Collaboration's Risk of Bias tool for Randomized trials.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Seventeen studies were identified (<i>N</i> = 2136), investigating armodafinil (<i>k</i> = 4, <i>N</i> = 1581), methylphenidate (<i>k</i> = 4, <i>N</i> = 84), bupropion (<i>k</i> = 4, <i>n</i> = 249), clonidine (<i>k</i> = 1, <i>n</i> = 70), lisdexamphetamine (<i>k</i> = 1, <i>n</i> = 25), mixed amphetamine salts (<i>k</i> = 1, <i>n</i> = 30), or modafinil (<i>k</i> = 2, <i>n</i> = 97). Three studies investigated cognition, four ADHD symptoms, and 10 the safety. Three studies found treatment-related ADHD symptom reduction: two involved methylphenidate and one amphetamine salts. One study found a trend towards pro-cognitive effects of modafinil on some cognitive domains. No increased risk of (hypo)mania was observed. Five studies had low risk of bias, eleven a moderate risk, and one a serious risk of bias.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Methylphenidate or mixed amphetamine salts may improve ADHD symptoms in BD. However, there is limited evidence regarding the effectiveness on cognition. The medications produced no increased mania risk when used alongside mood stabilizers. Further robust studies are needed to assess cognition in BD patients receiving psychostimulant treatment alongside mood stabilizers.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":"26 3","pages":"216-239"},"PeriodicalIF":5.4,"publicationDate":"2024-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bdi.13414","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140020890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experts by lived experience: Enhancing the patient-provider relationship through patient stories","authors":"Tammy Hua,&nbsp;Gregg Martin,&nbsp;Alex Leow","doi":"10.1111/bdi.13413","DOIUrl":"10.1111/bdi.13413","url":null,"abstract":"","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":"26 3","pages":"291-292"},"PeriodicalIF":5.4,"publicationDate":"2024-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139929933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolomic biomarkers for (R, S)-ketamine and (S)-ketamine in treatment-resistant depression and healthy controls: A systematic review","authors":"Rakesh Kumar,&nbsp;Nicolas A. Nuñez,&nbsp;Neha Joshi,&nbsp;Boney Joseph,&nbsp;Alessandra Verde,&nbsp;Ashok Seshadri,&nbsp;Alfredo B. Cuellar Barboza,&nbsp;Larry J. Prokop,&nbsp;Gustavo C. Medeiros,&nbsp;Balwinder Singh","doi":"10.1111/bdi.13412","DOIUrl":"10.1111/bdi.13412","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Ketamine is increasingly used for treatment-resistant depression (TRD) while its mechanism of action is still being investigated. In this systematic review, we appraise the current evidence of metabolomic biomarkers for racemic ketamine and esketamine in patients with TRD and healthy controls (HCs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A comprehensive search of several databases (Ovid MEDLINE®, Embase, and Epub Ahead of Print) was performed from each database's inception to June 29, 2022, in any language, was conducted. We included studies wherein the metabolomic biomarkers for racemic ketamine or esketamine were investigated in TRD or HCs. Our main outcomes were to examine changes in metabolites among patients treated with ketamine/esketamine and explore the association with response to ketamine/esketamine.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 1859 abstracts were screened of which 11 were included for full-text review. Of these, a total of five articles were included (<i>N</i> = 147), including three RCTs (<i>n</i> = 129) and two open-label trials (<i>n</i> = 18). All studies used racemic ketamine; one study additionally used esketamine. The included studies evaluated patients with treatment-resistant bipolar depression (<i>n</i> = 22), unipolar depression (<i>n</i> = 91), and HCs (<i>n</i> = 34). The included studies reported alteration in several metabolites including acylcarnitines, lipids, kynurenine (KYN), and arginine with ketamine in TRD. Studies suggest the involvement of energy metabolism, KYN, and arginine pathways. In HCs, acetylcarnitine decreased post-infusion, whereas inconsistent findings were observed after the ketamine infusion in TRD patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This systematic review provides preliminary evidence that ketamine may cause changes in several important pathways involved in energy metabolism and inflammation. Larger and more rigorous studies are needed.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":"26 4","pages":"321-330"},"PeriodicalIF":5.4,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139701704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Late-onset delirious mania: Does it ring a bell?","authors":"Maria Aa Hansen,&nbsp;Robert Bering,&nbsp;Anders Spanggård,&nbsp;Pedro Barata","doi":"10.1111/bdi.13411","DOIUrl":"10.1111/bdi.13411","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Bell's mania was first described in 1849, and other terms have been used to describe this condition, including delirious mania, mania with delirium, and excited delirium. However, no international diagnostic manual has included mania as an independent diagnostic tool. The criteria for delirious mania were proposed by Bond et al.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We present a case of a man without a personal or family psychiatric history who experienced his first manic episode of delirium and psychosis at 76 years old.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The case described in this study is compatible with mood disorders, the original description of Bell's mania, and Bond's definition of delirious mania. Although rare, extremely late-onset primary mania can occur without personal or family psychiatric history. The initial clinical presentation of delirium requires a thorough medical investigation, including magnetic resonance imaging (MRI) and lumbar puncture with neuronal antibodies. The addition of delirious mania to the group of bipolar disorders in future editions of <i>The International Classification of Diseases (ICD</i>) and <i>Diagnostic</i> and <i>Statistical Manual of Mental Disorders</i> (DSM) has therapeutic and prognostic implications. The Bond criteria can provide valuable information in this respect. Further investigations are necessary to clarify the pathophysiology and epidemiology of delirious mania.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":"26 4","pages":"331-334"},"PeriodicalIF":5.4,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bdi.13411","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139721490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anhedonia in bipolar depression treated with ketamine","authors":"Alina Wilkowska,&nbsp;Mariusz S. Wiglusz,&nbsp;Aleksandra Arciszewska-Leszczuk,&nbsp;Maria Gałuszko-Węgielnik,&nbsp;Wiesław J. Cubała","doi":"10.1111/bdi.13409","DOIUrl":"10.1111/bdi.13409","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Bipolar depression is the major cause of morbidity in patients with bipolar disorder. It affects psychosocial functioning and markedly impairs occupational productivity. Anhedonia is one of the most debilitating symptoms of depression contributing to treatment resistance. It correlates with suicidality, low quality of life, social withdrawal, and poor treatment response. Currently, there is no approved treatment specifically targeting anhedonia. Emerging evidence suggests that ketamine possesses anti-anhedonic properties in individuals with depression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The aim of this naturalistic open-label study was to investigate the effect of add-on ketamine treatment on anhedonia in treatment resistant bipolar depression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Our main interest was the change in patient-reported (Snaith-Hamilton Pleasure Scale) and rater-based anhedonia measure (Montgomery–Åsberg Depression Rating Scale-anhedonia subscale). The secondary aim was to analyze the score change in three Inventory of Depressive Symptomatology-Self Report (IDS-SR) domains: mood/cognition, anxiety/somatic, and sleep. Patients underwent assessments at several time points, including baseline, after the third, fifth, and seventh ketamine infusions. Additionally, a follow-up assessment was conducted 1 week following the final ketamine administration.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We found improvement in anhedonia symptoms according to both patient-reported and rater-based measures. The improvement in IDS-SR domains was most prominent in anxiety/somatic factor and mood/cognition factor, improvement in sleep factor was not observed. No serious adverse events occurred.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Add-on ketamine seems to be a good choice for the treatment of anhedonia in treatment resistant bipolar depression. It also showed a good effect in reducing symptoms of anxiety in this group of patients. Considering unmet needs and the detrimental effect of anhedonia and anxiety, more studies are needed on ketamine treatment in resistant bipolar depression.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":"26 4","pages":"356-363"},"PeriodicalIF":5.4,"publicationDate":"2024-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139688760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fostering networking opportunities and creating a community of early and mid-career clinicians and researchers within the International Society for Bipolar Disorders","authors":"Fabiano A. Gomes,&nbsp;Rebekah S. Huber,&nbsp;Sarah H. Sperry,&nbsp;Tamsyn E. Van Rheenen","doi":"10.1111/bdi.13410","DOIUrl":"10.1111/bdi.13410","url":null,"abstract":"&lt;p&gt;The International Society for Bipolar Disorders (ISBD) recognizes that empowering the next generation of professionals focused on bipolar disorder is critical for both the scientific progress of the discipline but also its survival as an organization. The Early and Mid-Career Committee (EMCC) was established to provide a platform from which the ISBD could nurture and support the career development of clinicians and researchers working in this space.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;The recent EMCC-led &lt;i&gt;Needs Assessment&lt;/i&gt; survey, which was targeted at early and mid-career (EMC) professionals, highlighted that both EMC clinicians &lt;i&gt;and&lt;/i&gt; researchers place great importance on the development of meaningful collaborations with peers and other professionals in the field.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; Most survey respondents reported actively trying to establish collaborations within their departments and with partners in other institutions and networking during conferences and presentations. Commonly reported facilitators of successful collaborations included (i) the existence of opportunities for networking, including via social media, conferences, and committees; (ii) the availability of supportive mentors that encouraged and facilitated the establishment of collaborations and (iii) pleasurable interpersonal interactions with other professionals that cultivated a positive collaborative relationship.&lt;/p&gt;&lt;p&gt;The future activities of the EMCC will be guided by the aforementioned priorities, which provide a tenable framework to support the needs of EMC clinicians and researchers focused on bipolar disorder. These activities will prioritize the inclusion of individuals of diverse backgrounds to foster networking in underdeveloped areas, such as in the Global South, as a means of mitigating inequality and reducing disparities in line with the guiding principles of equity, diversity, and inclusion. Although some initiatives, such as advocating for more representation and dedicated activities in scientific meetings are already in place and are part of the EMCC mission, the implementation of initiatives to address other priorities may take more time and effort. For instance, there will likely be financial barriers within the ISBD to expand travel funding for EMC members, so establishing new and creative partnerships with funding agencies and industry and offering a hybrid model that allows online participation and networking during the Annual Conference might be warranted. That said, as ISBD already promotes online activities there should be virtually no barriers to adapt the existing digital infrastructure and expertise to establish an online community connecting new and existing EMC members.&lt;/p&gt;&lt;p&gt;The EMCC recognizes that networking and collaboration are a critical means to enable innovative solutions to difficult problems. Fostering networking and collaboration is a priority of the EMCC, and the initiatives that will be executed to address this priority ","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":"26 2","pages":"186-187"},"PeriodicalIF":5.4,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bdi.13410","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139656535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is peripartum anhedonia a missing target?","authors":"Marianna Mazza,&nbsp;Giuseppe Marano","doi":"10.1111/bdi.13408","DOIUrl":"10.1111/bdi.13408","url":null,"abstract":"<p>The perinatal period is an extremely delicate phase that can involve a high risk for onset of depressive disorders. The Edinburgh Postnatal Depression Scale (EPDS) is a widely validated instrument for assessing perinatal depressive symptoms, including the dimension of anhedonia. There are studies suggesting that the neural mechanism underlying the occurrence of anhedonia in patients with major depressive disorder (MDD) and bipolar depression (BD) might be distinct. Anhedonia seems to represent a more stable and frequent symptom in women with postpartum bipolar relative to unipolar depressive disorder and is associated with significantly higher depressive symptom severity. Perinatal medicine is an important component of women's health. Treatment of anhedonia can be challenging, and the most effective treatment can be a combination of psychotherapy and medication, but the screening of anhedonia in peripartum women can prevent the development of other psychiatric disorders and maladaptive behaviors.</p>","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":"26 3","pages":"289-290"},"PeriodicalIF":5.4,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139665267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}